AbbVie’s growth engines outpace Humira erosion

Growth engines support a stronger outlook

AbbVie’s third-quarter results indicate that its newer immunology products are continuing to offset the erosion of Humira. The company reported adjusted earnings of $3.82 a share for the quarter ended September 2026, above the $3.74 estimate, and revenue of $17.4 billion, slightly ahead of a $17.36 billion forecast. Operational sales increased 10.5%, with SKYRIZI and RINVOQ posting double-digit growth.

AbbVie also raised its full-year 2026 EPS and sales guidance. The magnitude of the revenue beat was small, but the combination of broad product growth and a higher outlook suggests that management expects recent commercial momentum to persist through the remainder of the year.

Immunology now carries the replacement test

Immunology generated about $9.2 billion in quarterly revenue, rising 16.6% operationally. SKYRIZI and RINVOQ continued to offset declines in older products such as HUMIRA, whose U.S. net revenue fell 39.9% year over year to $372 million, while international revenue declined 16.8% to $311 million.

That contrast is the central commercial signal for AbbVie: newer products continued to grow while Humira declined, providing evidence of portfolio replacement without quantifying the full offset. The reported figures nevertheless do not quantify how much revenue is directly attributable to that substitution, so the scale of the replacement cannot be isolated precisely from the quarter alone.

Neuroscience adds a second source of momentum

Neuroscience revenue rose nearly 19.5% to about $3.4 billion, supported by VRAYLAR, UBRELVY, QULIPTA and the newly approved JUVMO. This performance broadens AbbVie’s growth foundation beyond immunology.

The reported evidence confirms product-level growth and JUVMO’s newly approved status, but does not provide product-by-product revenue or demand measures. Consequently, it supports a conclusion of expanding neuroscience performance rather than an order, procurement signal or quantified future sales contribution for any individual medicine.

Stronger cash generation carries balance-sheet risk

AbbVie generated about $14 billion in free cash flow during the first nine months of 2026, including nearly $2.7 billion in SKYRIZI royalty payments, and ended September with $10.8 billion in cash. The company also increased its quarterly dividend by 5.2%, marking its 14th consecutive year of dividend increases according to InvestingPro data.

The cash generation supports AbbVie’s ability to fund shareholder returns, although a separate Simply Wall St analysis highlighted continuing concerns about debt and negative equity. The market response was restrained: shares closed at $294.89, up 1.41%, and traded at $295 after hours. The muted reaction indicates that investors did not treat the quarter as a major change in AbbVie’s valuation, while the balance-sheet issue remains relevant to how investors assess that valuation.

Oncology and pricing remain the counterweight

Oncology and aesthetics were mixed. AbbVie reported oncology revenue of about $1.7 billion, with operational growth of only 0.9%, while Imbruvica sales declined. Simply Wall St attributed Imbruvica’s decline to pricing rules and competitive share pressure and warned that similar pressure on other oncology products could offset growth elsewhere.

That risk prevents the earnings result from establishing uniformly strong growth across AbbVie’s portfolio. Immunology and neuroscience are carrying the quarter, while the company’s ability to translate that momentum into durable earnings depends partly on how older-product erosion, oncology competition and pricing pressure evolve. The next observable test is whether SKYRIZI and RINVOQ can maintain their growth as AbbVie works against the raised full-year guidance and continued HUMIRA declines.

Industry and product implications